Ipamorelin

Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates growth hormone release by binding to ghrelin receptors in the pituitary gland. This pentapeptide promotes muscle growth, fat loss, and recovery without significantly affecting cortisol or prolactin levels.

Category: Compound Evidence: 6/10 Tier: Tier 3 (preliminary)

Origin & History

Ipamorelin is a synthetic peptide that mimics the action of ghrelin, a natural hormone. It is produced through peptide synthesis and is used primarily for its growth hormone-releasing properties.

Historical & Cultural Context

Developed in the late 20th century, Ipamorelin is used in research settings for its potential anti-aging and performance-enhancing effects.

Health Benefits

- Stimulates the release of growth hormone (GH) from the pituitary gland, supporting overall growth and cellular repair. - Promotes muscle growth and accelerates recovery by enhancing protein synthesis and reducing muscle breakdown. - Supports fat loss by increasing metabolism and encouraging the body to use stored fat for energy. - Improves sleep quality, which is essential for muscle repair and hormone balance. - Enhances bone density and strength by stimulating osteoblast activity. - Boosts collagen production, leading to healthier skin, hair, and connective tissue. - May improve immune function by supporting the regeneration of immune cells. - Offers a gentle, selective GH release without significant impact on cortisol or prolactin levels, reducing side effects.

How It Works

Ipamorelin binds selectively to growth hormone secretagogue receptors (GHS-R1a) in the anterior pituitary gland, triggering the release of endogenous growth hormone. Unlike other GHRPs, it demonstrates high selectivity for GH release without stimulating ACTH, cortisol, or prolactin secretion. The peptide mimics ghrelin's action but with greater specificity, leading to pulsatile GH release that follows natural circadian rhythms.

Scientific Research

Ipamorelin has been studied in animal models and early human trials, showing potential for growth hormone release and muscle growth. More research is needed.

Clinical Summary

Human studies on ipamorelin are limited, with most research conducted in animal models and small-scale clinical trials. A study in elderly adults (n=24) showed significant increases in growth hormone levels within 30 minutes of administration, with peak levels occurring at 45-60 minutes. Animal studies demonstrate improved body composition, with 15-20% increases in lean muscle mass and 10-15% reductions in body fat over 8-12 week periods. The current evidence suggests efficacy but requires larger, longer-term human trials for definitive clinical validation.

Nutritional Profile

- Composed of a sequence of amino acids.
- Administered via subcutaneous injection.
- Acts on the pituitary gland to release growth hormone.

Preparation & Dosage

Typical dosage ranges from 200 mcg to 300 mcg per day, administered via subcutaneous injection. Consult a healthcare provider before use.

Synergy & Pairings

GHRP-6, Creatine, BCAAs

Safety & Interactions

Common side effects include injection site reactions, mild headaches, and temporary flushing, typically occurring in 10-15% of users. Ipamorelin may interact with medications affecting blood glucose levels, as it can influence insulin sensitivity and glucose metabolism. It is contraindicated in individuals with active cancer, severe diabetes, or during pregnancy and breastfeeding due to insufficient safety data. Long-term effects remain unknown, and users should monitor for signs of acromegaly with extended use.